Biomarkers in psoriasis and psoriatic arthritis
Biomarkers in psoriasis and psoriatic arthritis
复制标题
DOI：
10.1136/annrheumdis-2012-203037
复制
发表时间：
2013-04-01
影响因子：
27.4
通讯作者：
Nestle, Frank O.
中科院分区：
文献类型：
--
作者：
Villanova, Federica;Di Meglio, Paola;Nestle, Frank O.
银屑病是一种常见的免疫介导的皮肤疾病，与20-30%的银屑病关节炎（PsA）患者有关。这两种疾病的免疫发病机制尚不完全清楚，因为它是遗传、环境和免疫因素之间复杂相互作用的结果。目前还没有治愈牛皮癣的方法，也没有能够准确预测疾病进展和治疗反应的特异性标志物。因此，迫切需要疾病预后和治疗反应的生物标志物来帮助临床医生根据客观适应症改善患者管理和预后。尽管已经做出了许多努力来确定牛皮癣/PsA生物标志物，但尚未将其转化为常规临床实践。在这篇综述中，我们总结了到目前为止在银屑病和PsA中发现的不同类型的可能的生物标志物，并讨论了发现生物标志物的新策略。
Psoriasis is a common immune-mediated disease of the skin, which associates in 20-30% of patients with psoriatic arthritis (PsA). The immunopathogenesis of both conditions is not fully understood as it is the result of a complex interaction between genetic, environmental and immunological factors. At present there is no cure for psoriasis and there are no specific markers that can accurately predict disease progression and therapeutic response. Therefore, biomarkers for disease prognosis and response to treatment are urgently needed to help clinicians with objective indications to improve patient management and outcomes. Although many efforts have been made to identify psoriasis/PsA biomarkers none of them has yet been translated into routine clinical practice. In this review we summarise the different classes of possible biomarkers explored in psoriasis and PsA so far and discuss novel strategies for biomarker discovery.